BioPharmSignal logoBioPharmSignal

Biotech News

Amgen wins FDA approval for late-stage oncology treatment

Amgen Inc. (AMGN)amgen.comFDA / regulatory

Amgen (AMGN) appears in the live feed after an FDA catalyst that can change the stock's tone quickly.

The source domain is amgen.com. BioPharmSignal keeps the ticker, timestamp, and source together so readers can move from signal to source without leaving the flow.

The original release is available below in a new tab so you can continue into the full source when needed.

Related news

BMYBMYBristol-Myers Squibb Company2026-08-13 21:12 EST

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

REGNRegeneron Pharmaceuticals2026-08-19 17:58 EST

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

IDYAIDEAYA Biosciences2026-08-31 10:00 EST

IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

ANIPANI Pharmaceuticals2026-09-23 10:55 EST

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

BNTXBioNTech2026-08-27 20:30 EST

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

REPLReplimune Group2026-08-06 20:00 EST

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

REPLReplimune Group2026-07-30 22:15 EST

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

TEVATeva Pharmaceutical Industries2026-09-28 20:00 EST

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

COGTCogent Biosciences2026-09-15 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

RVMDRevolution Medicines2026-08-26 16:59 EST

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

View all latest news

Amgen Inc.

Large-Cap Biotechnology Company Amgen is a global biotechnology company that discovers, develops, manufactures, and commercializes medicines using human biology, advanced genetics, and protein engineering. Its portfolio spans general medicine, cardiovascular disease, rare disease, inflammation, hematology, and oncology, supported by...

Recent company news

AMGNamgen.com2026-04-03 09:15 EST

FDA approves late-stage oncology treatment

AMGNamgen.com2026-04-01 08:05 EST

Management commentary keeps pipeline priorities in focus

AMGNnewswire2026-03-28 16:20 EST

Investors watch oncology and cardiometabolic launch cadence

AMGNsec.gov2026-03-21 07:50 EST

Regulatory calendar keeps Amgen in the spotlight

AMGNconference2026-03-15 10:10 EST

Pipeline updates reinforce the commercial-stage narrative

Stock data

Close
407.27 USD
Market cap
177.16B USD
Exchange
NASDAQ
Sector
Generics, Biopharma, Oncology, Immunotherapy
Location
Thousand Oaks, California